Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OX1Y
|
|||
| Former ID |
DIB001267
|
|||
| Drug Name |
Ad5-ENVA-48
|
|||
| Synonyms |
Ad26-ENVA-01; Ad5-HVR48-ENVA-01; HIV vaccine (ad35 vector), IAVI/Crucell; Recombinant envelope adenovirus 5 vaccine (HIV infection), Crucell/Harvard Medical School; Adenovirus vector vaccine (HIV infection), IAVI/Crucell/BIDMC/Harvard; HIV vaccine (rAd26 vector), IAVI/Crucell/Beth Israel Deaconess Medical Center/Harvard; HIV vaccine (AdVac, PER.C6), Crucell/IAVI/BIDMC/Harvard
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Phase 1 | [1] | |
| Company |
Crucell NV
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.